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It has been shown that a small number of patients with
advanced malignant melanoma (MM) respond to additive
hormonal treatments such as the anti-oestrogen tamoxifen
(Karakousis et al., 1980). Receptor studies have shown that
the expression of significant amounts of oestrogen receptors
is rare in MM. However, glucocorticoid receptors are a
common finding (Hawkins et al., 1980; Bhakoo et al., 1981;
Bojar et al., 1982). The observation that medroxy-
progesterone acetate (MPA) binds to the
glucocorticoid receptor in the same way as dexamethasone,
led to a phase II study to assess the therapeutic relevance of
the high glucocorticoid receptor levels in MM.
Eighteen outpatients with histologically confirmed MM
and measurable and progressive lesions, who were not
amenable to curative surgery were treated with high-dose
MPA. The patients had a performance status according to
the Karnofsky index above or at 70%. The characteristics of
patients are shown in Table I.
All patients received 1 g MPA per day as intramuscular
injection on days 1-10 and 200 mg MPA t.i.d. orally
thereafter. This treatment schedule was adapted from a
treatment schedule for advanced breast cancer and yields
MPA serum levels well above 100 ngml- (Miller et al.,
1985). Treatment was continued as long as disease
stabilisation or remission was achieved. The criteria for
response were as follows. Tumour progression was defined
as an increase of tumour size of more than 25% of any
measurable lesion or the appearance of new lesions. Partial
response was defined as a reduction of tumour size of more
than 50% of every measurable lesion without appearance of
new lesions. Complete response was defined as disappearance
of all measurable lesions.
All patients were evaluable for response. Duration of
treatment ranged from 13 days to 10 months (median 50
Table I Pretreatment characteristics of patients
Characteristic No. ofpatients
Entered/evaluated 18 / 18
Pretreatment
None 9
Tamoxifen 7
Chemotherapy 2
Metastatic sites
Lung 7
Liver 6
Lymph nodes 12
Only one site 7
More than one site 10
Median age in years (range): 45 (12-72).
days). A stabilisation of disease was observed in two patients
for 3 months. There were no objective responses. Toxicity
was moderate and similar to that reported for high-dose
MPA treatment in breast cancer. Weight gain of more than
3 kg was observed in three patients.
Our experience with high-dose medroxyprogesterone
acetate was negative and similar to that reported by Creagan
et al. (1982), who treated 20 patients with progesterone
megestrol acetate.
We conclude that HD-MPA has only little or no tumour-
reductive effect in advanced MM (response less than 20%
with 95% confidence). Thus, the high levels of glucocorticoid
receptors found in the majority of melanoma specimens and
their binding affinity to MPA seem not to be of therapeutic
relevance. In addition, high-dose MPA treatment is
associated with a higher level of toxicity, as compared to
tamoxifen, which is able to induce incidental tumour
reductions (Karakousis et al., 1980).
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